These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31547858)

  • 21. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uncommon breast malignancies: presentation pattern, prognostic issue and treatment outcome in an Italian single institution experience.
    Bareggi CM; Consonni D; Galassi B; Gambini D; Locatelli E; Visintin R; Runza L; Giroda M; Sfondrini MS; Onida F; Tomirotti M
    Tumori; 2013; 99(1):39-44. PubMed ID: 23548998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
    Bae MS; Seo M; Kim KG; Park IA; Moon WK
    Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials.
    Jensen MB; Nielsen TO; Knoop AS; Laenkholm AV; Balslev E; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):135-140. PubMed ID: 29168407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.
    Guth AA; Chun Kim J; Schwartz S; Montes J; Snyder RA; Axelrod D; Schnabel F
    Breast J; 2017 Mar; 23(2):177-181. PubMed ID: 28299888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytohistological correlation of grading in breast carcinoma.
    Lingegowda JB; MuddeGowda PH; Ramakantha CK; Chandrasekar HR
    Diagn Cytopathol; 2011 Apr; 39(4):251-7. PubMed ID: 21416638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma.
    Kim EJ; Kim SH; Park GE; Kang BJ; Song BJ; Kim YJ; Lee D; Ahn H; Kim I; Son YH; Grimm R
    J Magn Reson Imaging; 2015 Dec; 42(6):1666-78. PubMed ID: 25919239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancers with round lumps: correlations between imaging and anatomopathology.
    Larribe M; Thomassin-Piana J; Jalaguier-Coudray A
    Diagn Interv Imaging; 2014 Jan; 95(1):37-46. PubMed ID: 23932764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
    Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
    Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FEAT expression correlates with tumor size, PR status, HER2 expression, Ki67 index, and molecular subtype and predicts recurrence in breast cancer.
    Wang SM; Ye M; Zhou J; Ni SM; Wei QC
    Neoplasma; 2017; 64(1):123-130. PubMed ID: 27881013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.
    Jiang S; Hong YJ; Zhang F; Li YK
    Sci Rep; 2017 Oct; 7(1):13818. PubMed ID: 29062076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
    Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
    Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.